{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:01:27Z","timestamp":1792011687655,"version":"4.4.0"},"reference-count":45,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Domp\u00e9 U.S. Inc."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Neurotrophic keratopathy (NK) results from trigeminal nerve impairment, leading to loss of corneal sensation (CS), epithelial breakdown, and in advanced stages, stromal ulceration or perforation. Cenegermin, a recombinant human nerve growth factor, is the first and only FDA-approved therapy for NK, although existing studies are limited by small sample sizes. This systematic literature review evaluated cenegermin\u2019s effects on CS and corneal innervation (CI) in patients with NK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>English-language studies published between August 2018 and June 2024 measuring CS or CI after cenegermin treatment for NK were identified through PubMed and Embase. For studies reporting quantitative data, sample size-based weighting was applied to each study\u2019s reported or derived mean change. Weighted means were calculated by NK stage or overall, where applicable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 25 studies met the inclusion criteria. The pooled mean age was 61.8 years (range: 2\u201393 years). Most included patients with stage II (moderate; 19 studies) and stage III (severe; 17 studies) NK. Across 8 studies reporting quantitative CS outcomes and 3 studies reporting quantitative CI outcomes, the weighted mean improvement from baseline to 8 weeks post-treatment was 116.5% for CS (range: 78.3%\u2013259.3%) and 64.5% for CI (range: 39.1%\u2013188.9%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>An 8-week course of cenegermin led to improvements in CS and CI in patients with NK, with greater relative gains observed among those patients with more severe disease. While study design heterogeneity and small sample sizes may limit the generalizability of these findings, the data support cenegermin\u2019s role in promoting corneal nerve regeneration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10807683261429005","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:24:42Z","timestamp":1773901482000},"page":"403-419","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Systematic Literature Review on the Effect of Cenegermin on Corneal Sensation and Innervation in Patients with Neurotrophic Keratopathy"],"prefix":"10.1177","volume":"42","author":[{"given":"Simon S.M.","family":"Fung","sequence":"first","affiliation":[{"name":"University of California, San Francisco, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Campos","sequence":"additional","affiliation":[{"name":"ADVI Health, Washington, District of Columbia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7728-2013","authenticated-orcid":false,"given":"Justin","family":"Weiss","sequence":"additional","affiliation":[{"name":"ADVI Health, Washington, District of Columbia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Yermilov","sequence":"additional","affiliation":[{"name":"ADVI Health, Washington, District of Columbia, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2018.04.003"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.06.019"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/EB.S117261"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/11206721231222949"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2013.09.002"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.101039"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2021.1900282"},{"key":"e_1_3_4_9_1","volume-title":"StatPearls","author":"Gurnani B","year":"2025","unstructured":"8.Gurnani B, , Feroze KB, , Patel BC. Neurotrophic keratitis. In: StatPearls. StatPearls Publishing: Treasure Island, FL; 2025. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK431106\/"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40135-020-00254-w"},{"issue":"11","key":"e_1_3_4_11_1","first-page":"e11724","article-title":"A novel treatment for neurotrophic corneal ulcer using topical cenegermin (OXERVATETM) containing recombinant human nerve growth factor","volume":"12","author":"Ahuja AS","year":"2020","unstructured":"10.Ahuja AS, , Bowden FW, , Robben JL. A novel treatment for neurotrophic corneal ulcer using topical cenegermin (OXERVATETM) containing recombinant human nerve growth factor. Cureus 2020;12(11):e11724.","journal-title":"Cureus"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2023.2168485"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01289-w"},{"key":"e_1_3_4_14_1","unstructured":"13.Domp\u00e9. Domp\u00e9 receives FDA approval cenegermin eye drops first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis. Available from: https:\/\/www.dompe.com\/us\/media\/press-releases\/dompe-receives-fda-approval-cenegermin-eye-drops-first-in-class-recombinant-human-nerve-growth-factor-with-potential-to-completely-heal-rare-neurotrophic-keratitis\/ [Last accessed: June17 2025]."},{"key":"e_1_3_4_15_1","unstructured":"14.Domp\u00e9. Cenegermin eye drops receive European Union approval: The first biotechnological drug resulting from Domp\u00e9 research for the treatment of moderate to severe neurotrophic keratitis is Made in Italy. Available from: https:\/\/www.dompe.com\/us\/media\/press-releases\/cenegermin-eye-drops-receive-european-union-approval-the-first-biotechnological-drug-resulting-from-dompe-research-for-the-treatment-of-moderate-to-severe-neurotrophic-keratitis-is-made-in-italy\/ [Last accessed: June17 2025]."},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.02.022"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.08.020"},{"key":"e_1_3_4_18_1","volume-title":"StatPearls","author":"Adams BS","year":"2025","unstructured":"17.Adams BS, , Patel AR. Cenegermin. In: StatPearls. StatPearls Publishing: Treasure Island, FL; 2025. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK573069\/"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-023-00866-y"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_4_21_1","unstructured":"20.Campos C Yermilov I Darling T et al. Systematic literature review (SLR) on the effect of nerve growth factor (NGF) on corneal innervation in neurotrophic keratitis. Internet Archive. 2024. Available from: https:\/\/archive.org\/details\/osf-registrations-sez23-v1. [Last accessed: Nov13 2024]."},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-024-02356-6"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-023-00857-z"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2024.2322012"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1210179"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02236-6"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02237-5"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.08.014"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/11206721221094783"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/11206721221097584"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101649"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1159\/000525923"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101488"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.920688"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05431-6"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061602"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/1120672120953343"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002797"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/25158414221134598"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05229-4"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002554"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2021.04.003"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-1274-3675"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.04.036"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/coa.0000000000000029"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14548"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261429005","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10807683261429005","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261429005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:18:47Z","timestamp":1785147527000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10807683261429005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,9,1]]}},"alternative-id":["10.1177\/10807683261429005"],"URL":"https:\/\/doi.org\/10.1177\/10807683261429005","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]}}}